REVIEW PAPER
Pediatric inflammatory multisystem syndrome temporally associated with COVID-19 – a novel condition in children and adolescents
1
Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, Poland
2
1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
Submission date: 2021-03-03
Final revision date: 2021-04-24
Acceptance date: 2021-04-24
Publication date: 2021-07-01
Pediatr Pol 2021;96(2):115-120
KEYWORDS
TOPICS
ABSTRACT
In March 2020, World Health Organization (WHO) declared the outbreak of the coronavirus disease 2019 (COVID-19) a pandemic. Pediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) also known as multisystem inflammatory syndrome in children (MIS-C) is a new phenomenon highly correlated with COVID-19. Recent research suggests that this new disease in children and adolescents is associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It is a generalized inflammatory reaction suggestive of a likely autoimmune etiology. Symptoms of PIMS-TS are diverse and wide ranging. The disorder develops in children and adolescents as a result of dysregulation of the immune system, but the exact pathogenesis of PIMS-TS remains unknown. Consequently, the most effective types of therapy include supportive care, symptomatic and immunomodulating treatment. The ongoing international study of this condition may provide information on the treatment options, clinical trials and management process.
REFERENCES (40)
1.
Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, et al. A comprehensive review of COVID-19 characteristics. Biol Proced Online 2020; 22: 19.
2.
Liu XF, Xu XK, Wu Y. Mobility, exposure, and epidemiological timelines of COVID-19 infections in China outside Hubei province. Sci Data 2021; 8: 54.
3.
Asselah, T, Durantel D, Pasmant E, et al. COVID-19: Discovery, diagnostics and drug development. J Hepatol 2021; 74: 168-184.
4.
Dasgupta A, Kalhan A, Kalra S. Long term complications and rehabilitation of COVID-19 patients. J Pak Med Assoc 2020; 70: 131-135.
5.
Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020; 288: 192-206.
6.
Patel NA. Pediatric COVID-19: Systematic review of the literature. Am J Otolaryngol 2020; 41: 102573.
7.
Parri N, Lenge M, Buonsenso D, et al. Children with Covid-19 in Pediatric Emergency Departments in Italy. N Engl J Med 2020; 383: 187-190.
8.
Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 2020; 20: e276-e288.
9.
Lawrensia S, Henrina J, Wijaya E, et al. Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2: a New Challenge amid the Pandemic. SN Compr Clin Med 2020; 1-9.
10.
Ramcharan T, Nolan O, Lai CY, et al. Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital. Pediatr Cardiol 2020; 41: 1391-1401.
11.
Harwood R, Allin B, Jones CE, et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health 2021; 5: 133-141.
12.
Tracewski P, Ludwikowska K, Szenborn L, et al. The first case of pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) in Poland, complicated by giant coronary artery aneurysms. Kardiol Pol 2020; 78: 1064-1065.
13.
Evans C, Davies P. SARS-CoV-2 paediatric inflammatory syndrome. Paediatr Child Health 2020; 10.1016/j.paed.2020.12.003.
14.
Nakra NA, Blumberg DA, Herrera-Guerra A, et al.; Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children (Basel) 2020; 7: 69.
15.
Godfred-Cato S, Bryant B, Leung J, et al. COVID-19-Associated Multisystem Inflammatory Syndrome in Children – United States, March-July 2020. MMWR. Morb Mortal Wkly Rep 020; 69: 1074-1080.
16.
Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA 2020; 324: 259-269.
17.
Consiglio CR, Cotugno N, Sardh F, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell 2020; 183: 968-981.e7.
18.
Niño-Taravilla C, Espinosa-Vielma YP, Otaola-Arca H, et al. Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 Treated with Tocilizumab. Pediatr Rep 2020; 12: 142-148.
19.
Kaushik S, Aydin SI, Derespina KR, et al. Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection (MIS-C): A Multi-institutional Study from New York City. The J Pediatr 2020; 224: 24-29.
20.
Okarska-Napierała M, Ludwikowska KM, Szenborn L, et al. Pediatric Inflammatory Multisystem Syndrome (PIMS) Did Occur in Poland during Months with Low COVID-19 Prevalence, Preliminary Results of a Nationwide Register. J Clin Med 2020; 9: 3386.
21.
Okarska-Napierała M, Ludwikowska K, Książyk J, et al. Postępowanie z dzieckiem z wieloukładowym zespołem zapalnym powiązanym z COVID-19. Wytyczne grupy eksperckiej przy Polskim Towarzystwie Pediatrycznym i Konsultancie Krajowym.
23.
Radia T, Williams N, Agrawal P, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatr Respir Rev 2020; S1526-0542(20)30117-2.
24.
Davies P, Evans C, Kanthimathinathan HK, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health 2020; 4: 669-677.
25.
Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol 2021; 73: e13-e29.
26.
Fernández-Sarmiento J, De Souza D, Jabornisky R, et al. Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): a narrative review and the viewpoint of the Latin American Society of Pediatric Intensive Care (SLACIP) Sepsis Committee. BMJ Paediatr Open 2021; 5: e000894.
27.
Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr 2021; 1-16.
28.
Marczyńska M, Pokorska-Śpiewak M, Talarek E, et al. Postępowanie z dzieckiem z COVID-19. Zalecenia dla pediatrów oraz lekarzy medycyny rodzinnej w podstawowej opiece zdrowotnej oraz dla leczących dzieci zakażone SARS-CoV-2 w warunkach szpitalnych. Przegl Pediatr 2020; 4: 10-16.
29.
Felsenstein S, Willis E, Lythgoe H, et al. Presentation, Treatment Response and Short-Term Outcomes in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). J Clin Med 2020; 9: 3293.
30.
Carter MJ, Shankar-Hari M, Tibby SM. Paediatric Inflammatory Multisystem Syndrome Temporally-Associated with SARS-CoV-2 Infection: An Overview. Intensive Care Med 2021; 47: 90-93.
31.
Belhadjer Z, Méot M, Bajolle F, et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. Circulation 2020; 142: 429-436.
32.
Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med 2020; 383: 347-358.
33.
Toubiana J, Cohen JF, Brice J, et al. Distinctive Features of Kawasaki Disease Following SARS-CoV-2 Infection: a Controlled Study in Paris, France. J Clin Immunol 2021; 41: 526-535.
34.
Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol 2020; 20: 453-454.
35.
Perez-Toledo M, Faustini SE, Jossi SE et al. Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with Paediatric Inflammatory Multi-System Syndrome. Preprint. medRxiv 2020; 2020.06.05.20123117.
36.
White M, Tiesman B, Handforth J, et al. Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): the Evelina Experience. Arch Dis Child 2020; 105: 1025-1027.
37.
Guo L, Lu MP, Dong GJ, et al. Clinical and laboratory features of macrophage activation syndrome Chin J Contemp Pediatr 2017; 19: 188-192.
38.
George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med 2014; 5: 69-86.
39.
Diorio C, Henrickson SE, Vella LA, et al.; Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest 2020; 130: 5967-5975.
40.
Jackowska T, Marczyńska M, Peregud-Pogorzelski J. Guidance for paediatric emergency departments/rooms and departments of paediatrics on the management of a child suspected of or diagnosed with COVID-19. Pediatr Pol 2020; 95: 65-72.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
